MUC1 peptide vaccine mediated antitumor activity in non-small cell lung cancer

Expert Opinion on Biological Therapy

Volumn 11, Issue 8, 2011, Pages 987-990

  Sharma, Sherven ^a,b   Srivastava, Minu K ^a,b   Harris White, Marni ^a,b   Lee, Jay Moon ^a   Dubinett, Steven ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

cancer vaccine; immune therapy; lung cancer

Indexed keywords

BLP25 LIPOSOMAL VACCINE; CANCER VACCINE; DNA VACCINE; MUCIN 1; PEPTIDE VACCINE; TG4010 VACCINE; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; AMINO ACID SEQUENCE; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; LIPOSOMAL DELIVERY; LUNG NON SMALL CELL CANCER; PROGNOSIS; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MUCIN-1; VACCINES, SUBUNIT;

HARNESS;

EID: 79959882697     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2011.598146     Document Type: Review

References (5)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49
2. Butts C, Murray N, Maksymiuk A, et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 2005;23:6674-81 (Pubitemid 46190262)
3. Sangha R, Butts C. L-BLP25: a peptide vaccine strategy in non small cell lung cancer. Clin Cancer Res 2007;13:s4652-4
4. Vlad AM, Kettel JC, Alajez NM, et al. MUC1 immunobiology: from discovery to clinical applications. Adv Immunol 2004;82:249-93 (Pubitemid 38209513)
5. Corrales-Rodriguez L, Blais N, Soulieres D. Emepepimut-S for non-small cell lung cancer. Expert Opin Biol Ther 2011;11:1091-7